When are breakthrough therapies cost-effective?

BACKGROUND: An increasing proportion of novel drug approvals use accelerated pathways, with notable growth in the US Food and Drug Administration–designated breakthrough pathway in recent years. Breakthrough therapy (BT) designation suggests that these therapies offer substantial potential to improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Olchanski, Natalia, Lin, Pei-Jung, Yeh, Wei-Shi, Kowal, Stacey, Cohen, Joshua T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372966/
https://www.ncbi.nlm.nih.gov/pubmed/35737862
http://dx.doi.org/10.18553/jmcp.2022.28.7.732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372966/
https://www.ncbi.nlm.nih.gov/pubmed/35737862
http://dx.doi.org/10.18553/jmcp.2022.28.7.732

Ejemplares similares